Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases

February 5, 2014

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

NIH Seeks Public-Private Proposals for HIV Cure Research 5-year Awards Could Total up to $56 million

The National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung and Blood Institute (NHLBI), both part of the National Institutes of Health, today announced a major research funding opportunity designed to spur innovative academic-private sector research collaborations to develop novel approaches to eliminate HIV. NIAID and NHLBI expect to fund three to six grants for a total of roughly $11.2 million per year for five years through the new request for applications (RFA).
Scientific advances in recent years have led to growing optimism that an HIV cure is an attainable goal. In December 2013, the NIH announced it would invest an additional $100 million over a three-year period toward this goal, which includes research that focuses on sustained remission, that is maintaining undetectable virus levels in the absence of antiretroviral therapy, as well as completely eliminating the virus from the body.
The new RFA, called “Beyond HAART: Innovative Approaches to Cure HIV-1,” will support investigators who have three to four interrelated, research projects that combine basic science and preclinical research with translational research, such as test-of-concept studies in animals or humans.
Areas of interest include, but are not limited to
  • Cell-based approaches, including those based on hematopoietic stem cells, transplantation and new methods to enhance cell expansion and persistence of transferred cells
  • Novel gene therapy approaches, including research on new viral and host targets, delivery systems and targeting of relevant cells
  • Non-traditional antiviral strategies, such as miRNAs, siRNAs and gene-editing enzymes; targeting and delivery of same
  • Test-of-concept studies carried out in animals or humans
NIAID and NHLBI will accept applications through July 28, 2014. For more information about the RFA, see Beyond HAART: Innovative Approaches to Cure HIV-1 (U19).

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit
NIH...Turning Discovery Into Health ®

back to top

Last Updated February 05, 2014

Last Reviewed February 05, 2014